Transplantation osteoporosis

被引：15

作者：

Ebeling P.R. ^{[1
]}

机构：

[1] Department of Medicine (RMH/WH), University of Melbourne, Western Hospital, Footscray

来源：

Current Osteoporosis Reports | 2007年 / 5卷 / 1期

关键词：

Bone Mineral Density; Bone Loss; Femoral Neck; Alendronate; Zoledronic Acid;

D O I：

10.1007/BF02938620

中图分类号：

学科分类号：

摘要：

Transplantation is an established therapy for end-stage diseases of the kidney, endocrine pancreas, heart, liver, and lung, and for many hematologic disorders. Improved survival rates have been accompanied by increased recognition of previously neglected long-term complications of transplantation such as fractures and osteoporosis. Pretransplantation bone disease and immunosuppressive therapy result in rapid bone loss and increased fracture rates early after transplantation. Patients should be assessed and pretransplantation bone disease should be treated. Preventive therapy initiated in the immediate posttransplantation period is indicated in patients with osteopenia or osteoporosis, as further bone loss will occur in the first several months after transplantation. Long-term organ transplant recipients should also have bone mass measurement and treatment of osteoporosis. Bisphosphonates are the most promising approach for the management of transplantation osteoporosis. Active vitamin D metabolites may have additional benefits in reducing hyperparathyroidism, particularly after kidney transplantation. Large, multicenter treatment trials with oral or parenteral bisphosphonates and calcitriol are recommended. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：29 / 37

页数：8

共 57 条

[1]

Cohen A., Sambrook P., Shane E., Management of bone loss after organ transplantation, J Bone Miner Res, 19, pp. 1919-1932, (2004)

[2]

Cohen A., Ebeling P.R., Sprague S., Shane E., Transplantation osteoporosis, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, pp. 302-309, (2006)

[3]

Stehman-Breen C.O., Sherrard D.J., Alem A.M., Et al., Risk factors for hip fracture among patients with end-stage renal disease, Kidney Int, 58, pp. 2200-2205, (2000)

[4]

Alem A.M., Sherrard D.J., Gillen D.L., Et al., Increased risk of hip fracture among patients with end-stage renal disease, Kidney Int, 58, pp. 396-399, (2000)

[5]

Ball A.M., Gillen D.L., Sherrard D., Et al., Risk of hip fracture among dialysis and renal transplant recipients, JAMA, 288, pp. 3014-3018, (2002)

[6]

Shane E., Mancini D., Aaronson K., Et al., Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure, Am J Med, 103, pp. 197-207, (1997)

[7]

Monegal A., Navasa M., Guanabens N., Et al., Bone disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics, Osteoporos Int, 12, pp. 484-492, (2001)

[8]

Millonig G., Graziadei I.W., Eichler D., Et al., Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study, Liver Transpl, 11, pp. 960-966, (2005)

[9]

Ninkovic M., Love S.A., Tom B., Et al., High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation, Calcif Tissue Int, 69, pp. 321-326, (2001)

[10]

Tschopp O., Boehler A., Speich R., Et al., Osteoporosis before lung transplantation: Association with low body mass index, but not with underlying disease, Am J Transplant, 2, pp. 167-172, (2002)

← 1 2 3 4 5 6 →